[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008121876A3 - Non-fucosylated antibodies - Google Patents

Non-fucosylated antibodies Download PDF

Info

Publication number
WO2008121876A3
WO2008121876A3 PCT/US2008/058750 US2008058750W WO2008121876A3 WO 2008121876 A3 WO2008121876 A3 WO 2008121876A3 US 2008058750 W US2008058750 W US 2008058750W WO 2008121876 A3 WO2008121876 A3 WO 2008121876A3
Authority
WO
WIPO (PCT)
Prior art keywords
fucosylated
antibodies
fucosylated antibodies
therapeutic
provision
Prior art date
Application number
PCT/US2008/058750
Other languages
French (fr)
Other versions
WO2008121876A2 (en
Inventor
Mitchell Reff
Kandasamy Hariharan
Ann Maclaren
Original Assignee
Biogen Idec Inc
Mitchell Reff
Kandasamy Hariharan
Ann Maclaren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Mitchell Reff, Kandasamy Hariharan, Ann Maclaren filed Critical Biogen Idec Inc
Priority to EP08799727A priority Critical patent/EP2142569A2/en
Priority to US12/593,282 priority patent/US20130183288A1/en
Priority to CA002682382A priority patent/CA2682382A1/en
Publication of WO2008121876A2 publication Critical patent/WO2008121876A2/en
Publication of WO2008121876A3 publication Critical patent/WO2008121876A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provision of non-fucosylated therapeutic antibodies. More particularly non-fucosylated anti-CD20, anti-CD23 and anti-CD80 antibodies, which show enhanced antibody effector functions. Also provided are cells expressing the non-fucosylated antibodies and therapeutic methods using the non-fucosylated antibodies.
PCT/US2008/058750 2007-03-28 2008-03-28 Non-fucosylated antibodies WO2008121876A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08799727A EP2142569A2 (en) 2007-03-28 2008-03-28 Non-fucosylated antibodies
US12/593,282 US20130183288A1 (en) 2007-03-28 2008-03-28 Non-fucosylated antibodies
CA002682382A CA2682382A1 (en) 2007-03-28 2008-03-28 Non-fucosylated antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90864307P 2007-03-28 2007-03-28
US60/908,643 2007-03-28

Publications (2)

Publication Number Publication Date
WO2008121876A2 WO2008121876A2 (en) 2008-10-09
WO2008121876A3 true WO2008121876A3 (en) 2009-01-22

Family

ID=39598182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/058750 WO2008121876A2 (en) 2007-03-28 2008-03-28 Non-fucosylated antibodies

Country Status (4)

Country Link
US (1) US20130183288A1 (en)
EP (1) EP2142569A2 (en)
CA (1) CA2682382A1 (en)
WO (1) WO2008121876A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054288A2 (en) * 2008-11-07 2010-05-14 National Jewish Health Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs")
AR075982A1 (en) 2009-03-31 2011-05-11 Roche Glycart Ag COMBINATION THERAPY OF A AFUCOSILATED ANTIBODY AND ONE OR MORE OF THE SELECTED CYTOKINS OF GM-CSF HUMAN, M-CSF HUMAN AND / OR IL-3 HUMAN AND COMPOSITION
BR112012026707A2 (en) * 2010-04-27 2017-03-14 Roche Glycart Ag use of an afucosylated anti-cd20 antibody, composition comprising an afucosylated anti-cd20 antibody and method of treating cancer patients by administering an afucosylated anti-cd20 antibody
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US9464137B2 (en) 2011-12-13 2016-10-11 Glykos Finland Oy Glycoprotein
RU2698061C2 (en) * 2013-08-01 2019-08-21 Файв Прайм Терапьютикс, Инк. Afucosylated fgfr2iiib fibroblast growth factor receptor
JP6779873B2 (en) 2014-11-12 2020-11-04 メモリアル スローン ケタリング キャンサー センター Anti-chondroitin sulfate proteoglycan 4 antibody and its use
TW201713332A (en) * 2015-07-14 2017-04-16 協和醱酵麒麟有限公司 A therapeutic agent for a tumor comprising an IDO inhibitor administered in combination with an antibody
TW202304515A (en) 2015-11-23 2023-02-01 美商戊瑞治療有限公司 Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
IT201700009339A1 (en) * 2017-01-30 2018-07-30 Enea Agenzia Naz Per Le Nuove Tecnologie Lenergia E Lo Sviluppo Economico Sostenibile Engineered anti-CD20 antibodies and their uses in the medical field.
CN118416216A (en) 2017-05-16 2024-08-02 戊瑞治疗有限公司 Combination of anti-FGFR 2 antibodies and chemotherapeutic agents in cancer treatment
US20210188994A1 (en) * 2018-08-29 2021-06-24 United Biopharma Inc. Afucosylated antibodies and manufacture thereof
CN113274502B (en) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Compositions for specific type three-negative breast cancer immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
WO2002060484A1 (en) * 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
US20050260205A1 (en) * 1995-06-07 2005-11-24 Biogen Idec, Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260205A1 (en) * 1995-06-07 2005-11-24 Biogen Idec, Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
WO2002060484A1 (en) * 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BAGENSTOSE L M ET AL: "B7-1 and B7-2 co-stimulatory molecules are required for mercury-induced autoimmunity", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 127, no. 1, January 2002 (2002-01-01), pages 12 - 19, XP002502178, ISSN: 0009-9104 *
CZUCZMAN MS: "Anti-CD80 monoclonal antibody: galiximab", HAEMATOLOGICA REPORTS, vol. 1, no. 8, October 2005 (2005-10-01), pages 35 - 36, XP002502174, Retrieved from the Internet <URL:http://www.haematologicareports.org/2005/8/35.pdf> [retrieved on 20081029] *
CZUCZMAN MYRON S ET AL: "Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 19, 1 July 2005 (2005-07-01), pages 4390 - 4398, XP002484694, ISSN: 0732-183X *
FUKAI TOHRU ET AL: "The role of costimulatory molecules B7-1 and B7-2 in mice with experimental autoimmune uveoretinitis", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. 237, no. 11, November 1999 (1999-11-01), pages 928 - 933, XP002502176, ISSN: 0721-832X *
HARIHARAN K ET AL: "THERAPEUTIC ACTIVITY OF IDEC-114 (ANTI.CD80) AND RITUXIMAB (RITUXAN) IN B-CELL LYMPHOMA", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 11, PART 01, 16 November 2001 (2001-11-16), pages 608A, XP001079527, ISSN: 0006-4971 *
PERRIN PETER J ET AL: "Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis", JOURNAL OF NEUROIMMUNOLOGY, vol. 65, no. 1, 1996, pages 31 - 39, XP002502177, ISSN: 0165-5728 *
SATOH MITSUO ET AL: "NON-FUCOSYLATED THERAPEUTIC ANTIBODIES AS NEXT-GENERATION THERAPEUTIC ANTIBODIES", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 6, no. 11, 1 November 2006 (2006-11-01), pages 1161 - 1173, XP008078583, ISSN: 1471-2598 *
WANG Y ET AL: "Galiximab. Primatized anti-CD80 monoclonal antibody, treatment of non-Hodgkin's lymphoma", DRUGS OF THE FUTURE, vol. 32, no. 10, October 2007 (2007-10-01), pages 854 - 858, XP008098096, ISSN: 0377-8282 *
YAMANE-OHNUKI N ET AL: "Establishment of FUT8 knockout chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 87, no. 5, 5 September 2004 (2004-09-05), pages 614 - 622, XP002983153, ISSN: 0006-3592 *
YEE KAREN W L ET AL: "EMERGING DRUGS FOR CHRONIC LYMPHOCYTIC LEUKAEMIA", EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, vol. 11, no. 1, 1 March 2006 (2006-03-01), pages 167 - 189, XP008079660, ISSN: 1472-8214 *
YOUNES ANAS ET AL: "Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma", CLINICAL LYMPHOMA, US, vol. 3, no. 4, 1 March 2003 (2003-03-01), pages 257 - 259, XP008098109, ISSN: 1526-9655 *

Also Published As

Publication number Publication date
EP2142569A2 (en) 2010-01-13
US20130183288A1 (en) 2013-07-18
WO2008121876A2 (en) 2008-10-09
CA2682382A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008121876A3 (en) Non-fucosylated antibodies
WO2007140371A3 (en) Antibodies and immunoconjugates and uses therefor
WO2008052187A3 (en) Antibodies and immunoconjugates and uses therefor
WO2008055037A3 (en) Infusion devices and methods
WO2008054676A3 (en) Medical devices and methods of using the same
USD595145S1 (en) Combined bottle and stopper
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
IL204542A (en) Monoclonal antibodies specific for the protofibril form of beta-amyloid protein, compositions, methods and uses pertaining thereto
AU2013201592A1 (en) Improved vaccines and methods for using the same
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2007121131A3 (en) Medical devices including shape memory materials
ZA200800207B (en) Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
EP1962947A4 (en) Needle-free injection device
AP2010005379A0 (en) Anti-TRKA antibodies and derivatives.
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2010014258A3 (en) Conjugates having a releasable linkage
AU2016219681A1 (en) A sound absorbing device of the type adapted to cover the ears of a user
WO2007149932A3 (en) Methods and compositions for targeting hepsin
EP1727903A4 (en) Modified xylanases exhibiting improved expression
USD649266S1 (en) J channel
WO2010079510A3 (en) Anti-rhd monoclonal antibodies
CA118651S (en) Open-mouth container
WO2007102946A3 (en) Crystalline polypeptides
江医 On Research of Audiovisual Translation Variation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08799727

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2682382

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008799727

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12593282

Country of ref document: US